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2Abstract
Objectives
To determine the psychological response (thoughts, perceptions and affect) to a diagnosis of
pulmonary nodules following a novel antibody blood test and computed tomography (CT) scans within
a UK population.
Materials and methods.
This study was nested within a randomised controlled trial of a blood test (Early CDT®-Lung test),
followed by a chest x-ray and serial CT-scanning of those with a positive blood test for early detection
of lung cancer (ECLS Study). Trial participants with a positive Early CDT®-Lung test were invited to
participate (n=338) and those agreeing completed questionnaires assessing psychological outcomes
at 1, 3 and 6 months following trial recruitment. Responses of individuals with pulmonary nodules on
their first CT scan were compared to those without (classified as normal CT) at 3 and 6 months follow-
up using random effects regression models to account for multiple observations per participant, with
loge transformation of data where modelling assumptions were not met.
Results
There were no statistically significant differences between the nodule and normal CT groups in affect,
lung cancer worry, health anxiety, illness perceptions, lung cancer risk perception or intrusive thoughts
at 3 or 6 months post-recruitment. The nodule group had statistically significantly fewer avoidance
symptoms compared to the normal CT group at 3 months (impact of events scale avoidance (IES-A)
difference between means -1.99, 95%CI -4.18, 0.21) than at 6 months (IES-A difference between
means 0.88, 95%CI -1.32, 3.08; p-value for change over time =0.003) with similar findings using loge
transformed data.
Conclusion
3A diagnosis of pulmonary nodules following an Early CDT®-Lung test and CT scan did not appear to
result in adverse psychological responses compared to those with a normal CT scan.
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4Introduction
Lung cancer is the most common cause of cancer-related deaths worldwide.(1) During 2014
approximately 46,400 individuals in the United Kingdom (UK) were diagnosed with lung cancer.(2)
Despite the incidence of lung cancer decreasing(3), mortality rates remain high, with 1-year survival
rates ranging from 71% when diagnosed at stage 1 to 16% at stage 4.(4)
The National Lung Screening Trial (NLST), showed serial computed tomography (CT) scanning was
associated with a 20% reduction in lung cancer mortality.(5) However, screening has potential harms,
such as radiation exposure, the detection of non-clinically relevant findings, over-diagnosis and
psychosocial harms.(6-11) It is therefore important to ensure acceptability to the population being
screened(12), and that overall benefits outweigh the harms.(13)
Assessments of the psychosocial impact of lung cancer screening are limited to studies using CT
scanning. The NLST, Pittsburgh Lung Screening Study, and the UK Lung Cancer Screening (UKLS) Trial
found increased anxiety in those with true positive screening results compared to those with negative
results. The UKLS also found significantly higher cancer worry scale scores 2 weeks after receiving CT
scan results in those referred for a repeat CT scan compared to those with negative results. However,
absolute differences were small and not thought to be clinically important. (14-17) Additionally, the
Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON trial) and the Pittsburgh Lung
Screening Study found increased lung cancer specific distress in those with an indeterminate result,
which diminished over time.(16, 18, 19)
As screening with CT scanning becomes more widespread, more people will be found to have
incidental findings, such as pulmonary nodules. Pulmonary nodules are widely defined as round
lesions within the lung, less than 3cm in diameter and surrounded by normal lung tissue.(20, 21) The
NLST reported an incidence of pulmonary nodules of 25.9% in participants with a pack year history of
5at least 30 years.(5) Several studies used psychological measures to assess the negative impact of a
diagnosis of pulmonary nodules(22-25), finding increased emotional distress(22, 23), frustration and
fear (25) amongst those with nodules. Additionally, French individuals diagnosed with pulmonary
nodules reported lower health-related quality of life (HRQoL) (measured using the SF-36) compared
to the French general population.(24)
Our study assesses short and medium-term psychological responses amongst a sample of participants,
with or without pulmonary nodule(s) identified on their first CT scan, within the Early Cancer Detection
Test-Lung Cancer Scotland Study (ECLS Study).(26) This is a randomised controlled trial assessing the
effectiveness of a blood test for lung cancer screening, measuring autoantibodies against seven
antigens (Early CDT®-Lung test).(26, 27) A positive Early CDT®-Lung test is associated with a
significantly increased risk of malignancy in the presence of pulmonary nodules 4-20mm in
diameter(28), and the consequent potential for adverse psychological effects. This study is therefore
timely in assessing psychological impacts of this test and subsequent CT scanning.
Methods
This paper presents data on a sub-sample of participants in the ECLS study. Current or ex-smokers
aged 50-75 years, with at least 20 pack-years, or fewer pack-years with a first-degree relative with
lung cancer from Greater Glasgow and Clyde or Tayside, were randomised 1:1 to an Early CDT®-Lung
test group or a non-screened control group. All trial participants were asked to complete a baseline
questionnaire preceding awareness of group allocation. Those with positive Early CDT®-Lung tests
were invited for a chest x-ray, followed by a CT scan, and then 6-monthly CT scans for 2 years. Prior
to these, they were given information explaining the investigations and the possibility of finding a
pulmonary nodule on their CT scan. Individuals were informed of their CT scan result in writing.
6Participants who had previously consented to be contacted and those with a positive Early CDT®-Lung
test were invited to participate in this nested psychological outcomes study. Those agreeing
completed additional questionnaires at 1, 3, 6, 12, 18 and 24 months collecting data on psychological
and behavioural outcomes. Participants were sent a £5 gift voucher for each questionnaire
completed. Postal and telephone reminders were used for non-responders. No further
questionnaires were sent to participants who were non-responsive to two consecutive
questionnaires. On completing the 1-month questionnaire, all participants would have been aware
that their Early CDT®-Lung test was positive, but 58% of participants had not yet had their CT scan,
18% had been scanned within the last 7 days, 37% within the last 14 days and 8% more than 14 days
previously. Consequently, at 1-month follow-up most participants will not have known their CT scan
results. The analyses presented in this paper are therefore confined to the psychological outcomes of
Early CDT®-positive group participants who completed baseline and at least one follow-up
questionnaire at 3 or 6 months. Participants were categorised into the nodule group if pulmonary
nodule(s) ≤ 8mm in diameter were present on their first CT scan and into the normal CT group if they 
were absent (normal CT group participants may have had previously known stable pathology). Study
ineligibility criteria can be found in Figure 1.
Data collection
Baseline information was collected at trial recruitment, between December 2013 and April 2015 and
included age, gender, smoking history, ethnic group, marital status, postcode, age at leaving full time
education, employment status, family history of lung cancer (first-degree relative) and antidepressant
medication use.
Psychological measures included the positive and negative affect schedule (PANAS)(29), lung cancer
worry scale (LCWS)(30), health anxiety subscale (HAS) of the health orientation scale(31), the impact
of events scale (IES)(32), the revised illness perception questionnaire-adapted for lung cancer
7(IPQ-R)(33), and lung cancer risk perception. The time points at which these were collected,
descriptions and internal consistency of measures are shown in Supplementary Table 1.
Analysis
Data analysis was undertaken using Stata Statistical Software version 13.1.(34) Baseline
characteristics of those in the normal CT and nodule groups were described using frequencies and
percentages for categorical data and medians and interquartile ranges (IQR) for non-normally
distributed continuous data. For ease of interpretation, means and standard deviations are also
presented. Groups were compared using chi-squared tests and Mann-Whitney U tests for categorical
and continuous variables respectively. Fisher’s exact test was used for ethnicity due to small values.
Multilevel (random effects) regression models were used to compare psychological measures
between the normal CT and nodule groups over time and to take account of multiple observations per
participant. Linear models were used for continuous variables and logistic models for categorical
variables. Models were adjusted for study centre, age group (50-54, 55-59, 60-64, 65-69, 70-74, 75-79
years), sex, smoking status, time (3 and 6 months) and where measured, baseline value of the
outcome variable. Analyses were repeated additionally adjusting for baseline antidepressant use and
family history of lung cancer.
Linearity of continuous covariates was checked by adding higher order terms to models. Differences
in outcomes over time between the normal and CT and nodule groups were assessed by adding a
group by time interaction and using likelihood ratio tests with p<0.01 taken as significant.
Between-group differences at each time point were estimated from these models. Model assumptions
were checked by plotting residual values and by excluding observations with large residual values (<-
3, >3). Where residuals were not normally distributed or variance was not constant, continuous
outcome measures were loge transformed (adding 1 to the IES-I and IES-A scores before
8transformation as some participants scored zero) and model assumptions were re-checked. Where
loge transformed models met assumptions better, we present findings on the original scale and the
loge transformed scale for ease of interpretation. We were unable to find a single standardised
method for handling missing data for the psychological measures. Single missing values were
therefore replaced with the mean or subscale score for the participant for PANAS, HAS, LCWS Impact
Score and IES. When more than one value was missing the scale score was considered to be missing.
Results
Three hundred and thirty eight Early CDT®-Lung test-positive ECLS trial participants took part in the
psychological outcomes study, 269 (174 in the normal CT group and 95 in the nodule group) of whom
were eligible to be included in the analyses presented in this paper (Figure 1). Response rates to
follow-up questionnaires were high. The analysis included 95% at 3 months and 94% at 6 months.
All participants were aware of their CT scan result on completing the 3-month questionnaire.
Baseline demographic and psychological measures
Table 1 shows baseline demographic characteristics by nodule status. There were no statistically
significant differences between the nodule and normal CT groups. Psychological measures at baseline
are shown in Table 2. The only statistically significant difference was that nodule group participants
had significantly higher (P=0.04) positive affect PANAS scores than normal CT group participants
(median (IQR) 37.4 (27, 41.6) vs. 32 (26.7, 39)).
Psychological measures at 3 and 6 months follow-up
Psychological measure scores at 3 and 6 months are shown in Table 3 and Table 4 shows adjusted
differences between means and odds ratios comparing the nodule to the normal CT group at 3 and 6
months. The nodule group had statistically significantly fewer avoidance symptoms compared to the
normal CT group at 3 months (difference between means in impact of events scale avoidance (IES-A)
9score -1.99, 95%CI -4.18, 0.21) than at 6 months (difference between means in IES-A score 0.88, 95%CI
-1.32, 3.08; P-value for change over time=0.003). However, the differences in means between the
nodule and normal CT groups were small at both time points. Table 5 shows differences between the
means of loge transformed data for outcomes where model assumptions were better met using
transformed data. Findings were similar to those using data on the original scale with lower IES-A
scores in the nodule than the normal CT group at 3 months (difference in loge transformed means
-0.34 (-0.65, -0.04) than at 6 months (difference in loge transformed means -0.06 (-0.36, 0.24)) but the
change over time did not reach statistical significance (P=0.04). No other statistically significant
differences between means or odds ratios were seen over time. Adjusting the models for whether
participants took antidepressant medication at baseline or had a family history of lung cancer had
little impact on the findings. Models were robust to exclusion of observations with large residual
values.
Discussion
Summary
This study demonstrates that a diagnosis of pulmonary nodules on a CT scan following an Early CDT®-
Lung positive result for lung cancer screening does not result in an adverse psychological response in
relation to affect, health anxiety, thought intrusion and illness perception compared to those who had
a normal CT scan in both the short and medium-term. Although those in the nodule group had
statistically significantly fewer avoidance behaviours than those in the normal CT group at 3 months
than at 6 months, the differences between the mean scores in the nodule and normal CT groups were
small at both time points.
Strengths and limitations
To our knowledge, this is the first study examining the psychological impact of receiving a pulmonary
nodule diagnosis following a novel antibody test and chest CT scan within a UK population. Strengths
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of our study include use of a range of psychological outcome measures, which included positive as
well as negative psychological responses, measures were repeated at multiple time points, a very high
follow-up rate and analyses were adjusted for baseline measures where possible. However, it is
possible that there may be small but potentially clinically important differences, which we did not
have sufficient power to detect. Although a lower p-value (0.01) was used for significance testing of
changes in scores between groups over time, multiple significance testing may have resulted in
significant findings for the IES avoidance score. However, even if our IES Avoidance score findings are
not due to type 1 error, differences in mean scores between the nodule and normal CT group were
small and unlikely to be clinically meaningful.(18) As we did not know whether participants had
received their CT scan result at the time of completing the 1-month questionnaire, this study does
not evaluate the immediate response to receiving a pulmonary nodule diagnosis.
Comparison with existing literature
Previous studies examining the psychological impact of a pulmonary nodule diagnosis have found
contrasting results.(18, 19, 24, 35, 36) Two studies in America found that individuals diagnosed with
pulmonary nodules reported emotional distress (measured using the IES) shortly after diagnosis (time
not specified)(35) and up to 2 or more years after diagnosis (19, 36).These findings differ from our
study and those of the NELSON trial, with the latter showing an early (2 months after diagnosis)(18)
and temporary clinically important increase in IES scores in individuals with nodules.(19) Additionally,
the NELSON trial did not find that health-related quality of life (HRQoL) was affected by a pulmonary
nodule diagnosis (19), which contrasts with a study in France.(24) This found a significantly lower
HRQoL at 6-months post-diagnosis in those with pulmonary nodules compared to the French general
population.(24) There are multiple factors that could explain the differences seen between these
studies and ours. These include differences in screening procedures (our study used the Early CDT®-
Lung test to identify those for CT scanning whereas other studies used CT screening alone or included
participants found to have pulmonary nodules during routine clinical care), study populations, timing
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of questionnaire administration, definitions of pulmonary nodules, mode of nodule detection
(screened versus incidentally detected), whether the study compared to a control group and whether
adjustments were made for baseline measures. Additionally, our study participants received
information explaining pulmonary nodules prior to their radiological investigations and enclosed with
their CT scan results.
It is not possible to directly equate the findings of this study with those of the UKLS, which did not
compare individuals with pulmonary nodules to those with a normal CT.(15, 17) Participants with
pulmonary nodules will have been included in the UKLS “repeat scan required group” for the 2-week
outcomes analysis and in the “false positive” group for the up to 2-years outcome analysis. A
statistically significant, but not clinically important, increase in lung cancer worry was found at 2 weeks
in those needing repeat scans compared to those with a negative CT scan result. No other statistically
significant or clinically important differences were found in lung cancer worry, anxiety or depression
at 2 weeks or up to 2 years, which is consistent with our findings.
There are several potential explanations for our finding that participants in the nodule group had a
more positive psychological response (lower avoidance scores) than the normal CT group. It is possible
that receiving a positive Early CDT®-Lung test psychologically prepared participants to receive an
abnormal CT scan result, leading to a more positive psychological response than in studies where the
CT scan is the first abnormal result a participant receives. Furthermore, receiving a diagnosis of
pulmonary nodules after a positive Early CDT®-Lung test may have provided participants with
reassurance, as this may be perceived as an “explanation” for the positive Early CDT®-Lung test, whilst
those with a normal CT scan may have interpreted this as contradictory to the blood test finding, and
experienced a lack of reassurance. It is also possible that participants with a positive Early CDT®-Lung
test were preparing themselves psychologically to receive a CT result suspicious for lung cancer, and
a diagnosis of pulmonary nodules may have been perceived as a much more favourable outcome, with
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a more positive psychological response. The manner in which the CT results were communicated may
also have been important in determining the psychological response. Those with pulmonary nodules
were sent their results by letter. This said the scan was satisfactory but had shown small nodules
within one of the lungs which were less than 8mm in size and were most likely to be of little health
concern. The letter also offered the option to discuss their scan results face-to-face with a doctor from
the study team. In addition, participants were advised that the nodules would be monitored with
further CT scans and any changes in nodules would result in a face-to-face discussion with a doctor.
There was a also a small but statistically significant difference in positive affect scores at baseline, with
the nodule group having a higher score than those with a normal CT. Higher positive affect scores have
been associated with a lower incidence of psychological illness,(37) so this may also potentially explain
our finding of lower avoidance scores in those with nodules than in those with a normal CT at 3
months.
Implications for research and practice
Our findings provide some reassurance to clinicians concerned about the potential harms of lung
cancer screening using a novel blood antibody test followed by serial CT scanning, should it be more
widely implemented. There is likely to be little impact on health services in terms of emotionally
distressed patients seeking help after pulmonary nodules being found on screening CT scans. Further
work is required to explore the short-term impact (i.e. within a month) of a diagnosis of pulmonary
nodules in the context of a screening programme and patients’ understanding of the results of both
blood tests and CT scans, and the impact of their understanding on psychological responses.
Trial Registration
ClinicalTrials.gov: NCT01925625.
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Figure 1. Number of ECLS participants eligible for inclusion within the study at each questionnaire
time-point.
Table 1. Psychological measures included in the questionnaires, with a brief description of each
measure.
Table 2. Demographic characteristics at baseline amongst participants in the nodule group and those
in the normal CT group (% indicates column percentage unless otherwise stated).
Table 3. Psychological measures at baseline amongst participants in the nodule group and those in
the normal CT group (% indicates column percentage unless otherwise stated).
Table 4. Psychological measures at 1, 3 and 6 months amongst participants in the nodule group and
those in the normal CT group (% indicates column percentage unless otherwise stated).
Table 5. Difference between means and odds ratios for psychological measures at 1, 3 and 6 months
comparing participants in the nodule group to those in the normal CT group.
Figure 1. Number of ECLS participants eligible for inclusion within the study at each questionnaire time-point.
*these participants were also sent the next follow-up questionnaire
Table 1. Demographic characteristics at baseline amongst participants in the nodule group and those in the
normal CT group (% indicates column percentage unless otherwise stated).
Variable
Nodule Normal CT
Statistical Test
n = 95 (%) n = 174 (%)
Study Centre
Glasgow
Tayside
72 (75.8)
23 (24.2)
123 (70.7)
51 (29.3)
χ²(1) = 0.80, p = 0.37
Age (years - median (IQR*))
50-54 years
55-59 years
60-64 years
65-69 years
70-74 years
75-79 years
61 (56, 67)
17 (17.9)
22 (23.2)
21 (22.1)
23 (24.2)
12 (12.6)
0 (0)
60 (55, 66)
37 (21.3)
48 (27.6)
31 (17.8)
40 (23.0)
15 (8.6)
3 (1.7)
z = -1.30, p = 0.19
χ²(5) = 4.06, p = 0.54
Gender
Male
Female
39 (41.1)
56 (58.9)
80 (46.0)
94 (54.0)
χ²(1) = 0.60, p = 0.44
Smoking Status
Current smoker
Ex-smoker
50 (52.6)
45 (47.4)
88 (50.6)
86 (49.4)
χ²(1) = 0.10, p = 0.75
Smoking Pack-year (median (IQR)) 35 (26, 48) 32.5 (25, 49) z = -0.83, p = 0.41
Ethnic Origin
White British
Other
[0]
93 (97.9)
2 (2.1)
[4]
165 (97.1)
5 (2.9)
Fisher’s exact p = 1.00
Marital Status
Single
In a relationship/married/civil partnership
Widowed
Separated/divorced
[0]
5 (5.3)
67 (70.5)
10 (10.5)
13 (13.7)
[5]
15 (8.9)
103 (61.0)
17 (10.0)
34 (20.1)
χ²(3) = 3.34, p = 0.34
Scottish Index of Multiple Deprivation
(Rank)
1-1395 (most deprived)
1396-2790
2791-4186
4187-5581
5582-6976 (least deprived)
35 (36.8)
27 (28.4)
14 (14.7)
8 (8.4)
11 (11.6)
68 (39.1)
42 (24.1)
27 (15.5)
23 (13.2)
14 (8.1)
χ²(4) = 2.60, p = 0.63
Prescribed medication for low mood
Yes
No
[1]
11 (11.7)
83 (88.3)
[4]
30 (17.7)
140 (82.4)
χ²(1) = 1.63, p = 0.20
Age at leaving full-time education (years -
median (IQR))
[2]
16 (15, 16)
[7]
16 (15, 16) z = 0.29, p = 0.77
Work Status
Employed
Unemployed
Retired/other
[0]
40 (42.1)
16 (16.8)
39 (41.1)
[5]
75 (44.4)
33 (19.5)
61 (36.1)
χ²(2) = 0.70, p = 0.70
First degree relative with lung cancer
No
Yes
70 (73.7)
25 (26.3)
115 (66.1)
59 (33.9)
χ²(1) = 1.65, p = 0.20
[missing values] *Interquartile range
Table 2. Psychological measures at baseline amongst participants in the nodule group and those in the normal
CT group (% indicates column percentage unless otherwise stated).
Psychological Measure Nodule
n = 95 (%)
Normal CT
n = 174 (%)
Statistical
Test
Positive and Negative Affect Schedule (PANAS)
Positive affect score (median (IQR*))
(mean (SD**))
Negative affect score (median (IQR))
(mean (SD))
[3]
37.4 (27, 41.6)
34.5 (9.2)
13 (11, 18)
15.6 (6.4)
[5]
32 (26.7, 39)
32.4 (8.8)
13 (11, 18)
15.7 (6.5)
z = -2.02
p = 0.04
z = -0.06
p = 0.96
Lung Cancer Worry Scale
How worried are you about getting lung cancer someday?
Not worried
Worried
What is your current anxiety level about the results of
future tests/treatments?
Not anxious
Anxious
Impact of worry
Median (IQR)
(mean (SD))
[2]
46 (49.5)
47 (50.5)
[2]
87 (93.6)
6 (6.4)
[2]
2 (2, 3)
2.9 (1.3)
[2]
66 (38.4)
106 (61.6)
[2]
153 (89.0)
19 (11.0)
[2]
3 (2, 3)
3.0 (1.4)
χ²(1) = 3.04
p = 0.08
χ²(1) = 1.49
p = 0.22
z = 1.44
p = 0.15
Illness Perception Questionnaire (IPQ-R)
What I do can affect my risk of getting lung cancer
Agree
Disagree
When I think about my risk of getting lung cancer I get
upset
Agree
Disagree
I do not know how likely it is that I might get lung cancer
Agree
Disagree
Finding lung cancer early can improve my chances of
survival
Agree
Disagree
Lung cancer would have a big impact on my life
Agree
Disagree
Lung cancer lasts for a long time
Agree
Disagree
A blood screening test can accurately detect lung cancer
Agree
Disagree
[1]
85 (90.4)
9 (9.6)
[1]
43 (45.7)
51 (54.3)
[2]
60 (64.5)
33 (35.5)
[2]
88 (94.6)
5 (5.4)
[2]
89 (95.7)
4 (4.3)
[2]
60 (64.5)
33 (35.5)
[1]
60 (63.8)
34 (36.2)
[4]
153 (90.0)
17 (10.0)
[4]
78 (45.9)
92 (54.1)
[6]
116 (66.7)
56 (33.3)
[2]
165 (95.9)
7 (4.1)
[3]
167 (97.7)
4 (2.3)
[2]
106 (61.6)
66 (38.4)
[3]
106 (62.0)
65 (38.0)
χ²(1) = 0.01
p = 0.91
χ²(1) = 0.001
p = 0.98
χ²(1) = 0.12
p = 0.73
χ²(1) = 0.24
p = 0.63
χ²(1) = 0.79
p = 0.37
χ²(1) = 0.22
p = 0.64
χ²(1) = 0.09
p = 0.77
Lung Cancer Risk Perception
What are the chances that you will develop lung cancer
over the next 5 years?
≤ 0.4 % (low risk)/Don't know 
≥ 1 % (high risk) 
Compared to other people of your age and sex, how likely
are you to develop lung cancer over the next 5 years?
Less likely/Don't know
More likely
[0]
85 (89.5)
10 (10.5)
[0]
50 (52.6)
45 (47.4)
[2]
153 (89.0)
19 (11.0)
[2]
82 (47.7)
90 (52.3)
χ²(1) = 0.02
p = 0.90
χ²(1) = 0.60
p = 0.44
[Missing values] *Interquartile range **Standard deviation
Table 3. Psychological measures at 3 and 6 months amongst participants in the nodule group and those in the normal CT group (% indicates column percentage unless
otherwise stated).
Psychological Measure 3 months 6 months
Nodule
n=91 (%)
Normal CT
n=165 (%)
Nodule
n=91 (%)
Normal CT
n=163 (%)
Positive and Negative Affect Schedule (PANAS)
Positive affect score
Median (IQR*)
(mean (SD**))
Negative affect score
Median (IQR)
(mean (SD))
[1]
32.5 (25-40)
32.1 (10.0)
[1]
14 (11, 22)
16.7 (7.6)
[3]
30 (24-35)
29.3 (8.5)
[3]
13 (11, 20)
16.8 (8.0)
[1]
34.5 (26-40)
32.8 (10.2)
[1]
14 (10, 21)
16.4 (7.8)
[2]
30 (23-36)
29.7 (9.2)
[2]
14 (11, 20)
16.5 (7.1)
Lung Cancer Worry Scale
How worried are you about getting lung cancer someday?
Not worried
Worried
What is your current anxiety level about the results of future
tests/treatments?
Not anxious
Anxious
Impact of worry
Median (IQR)
(mean (SD))
[0]
39 (42.9)
52 (57.1)
[1]
73 (81.1)
17 (18.9)
[1]
3 (2, 4)
3.3 (1.7)
[0]
62 (37.6)
104 (62.4)
[0]
133 (80.6)
32 (19.4)
[1]
3 (2, 4)
3.4 (1.7)
[0]
39 (42.9)
52 (57.1)
[1]
71 (78.9)
19 (21.1)
[2]
2 (2, 4)
3.2 (1.7)
[0]
56 (34.4)
107 (65.6)
[1]
132 (81.5)
30 (18.5)
[1]
3 (2,4)
3.4 (1.7)
Illness Perception Questionnaire (IPQ-R)
What I do can affect my risk of getting lung cancer
Agree
Disagree
When I think about my risk of getting lung cancer I get upset
Agree
Disagree
I do not know how likely it is that I might get lung cancer
Agree
Disagree
Finding lung cancer early can improve my chances of survival
Agree
Disagree
[1]
80 (88.9)
10 (11.1)
[1]
39 (43.3)
51 (56.7)
[2]
53 (59.5)
36 (40.5)
[0]
86 (94.5)
5 (5.5)
[3]
147 (90.7)
15 (9.3)
[3]
71 (43.8)
91 (56.2)
[3]
95 (58.6)
67 (41.4)
[2]
152 (93.3)
11 (6.7)
[0]
84 (92.3)
7 (7.7)
[1]
42 (46.7)
48 (53.3)
[2]
40 (44.9)
49 (55.1)
[0]
84 (92.3)
7 (7.7)
[2]
147 (91.3)
14 (8.7)
[1]
75 (46.3)
87 (53.7)
[1]
89 (54.9)
73 (45.1)
[0]
151 (92.6)
12 (7.4)
Lung cancer would have a big impact on my life
Agree
Disagree
Lung cancer lasts for a long time
Agree
Disagree
A blood screening test can accurately detect lung cancer
Agree
Disagree
[0]
87 (95.6)
4 (4.4)
[0]
56 (61.5)
35 (38.5)
[2]
52 (58.4)
37 (41.6)
[1]
157 (95.7)
7 (4.3)
[3]
98 (60.5)
64 (39.5)
[3]
92 (56.8)
70 (43.2)
[1]
86 (95.6)
4 (4.4)
[1]
51 (56.7)
39 (43.3)
[0]
49 (53.9)
42 (46.2)
[1]
156 (96.3)
6 (3.7)
[3]
91 (56.9)
69 (43.1)
[0]
81 (49.7)
82 (50.3)
Lung Cancer Risk Perception
What are the chances that you will develop lung cancer over the next 5
years?
≤ 0.4 % (low risk) / Don't know 
≥ 1 % (high risk) 
Compared to other people of your age and sex, how likely are you to
develop lung cancer over the next 5 years?
Less likely / Don't know
More likely
[0]
65 (71.4)
26 (28.6)
[0]
37 (40.7)
54 (59.3)
0]
118 (71.5)
47 (28.5)
[1]
57 (34.8)
107 (65.2)
[1]
61 (67.8)
29 (32.2)
[0]
31 (34.1)
60 (65.9)
[0]
121 (74.2)
42 (25.8)
[0]
64 (39.3)
99 (60.7)
Health Anxiety Subscale (HAS)
Median (IQR)
(mean (SD))
[0]
5 (3, 10)
7.2 (5.7)
[0]
6 (4, 11)
8.0 (5.3)
[0]
5 (3, 9)
7.0 (5.8)
[0]
6 (3, 12)
7.8 (5.5)
Impact of Events Scale
Intrusion score
Median (IQR)
(mean (SD))
Avoidance score
Median (IQR)
(mean (SD))
[1]
0.5 (0, 6)
4.2 (6.9)
[1]
0.5 (0, 5)
4.7 (8.2)
[0]
2 (0, 7)
4.7 (6.6)
[0]
2 (0, 10)
6.4 (8.8)
[0]
0 (0, 6)
4.1 (6.8)
[0]
0 (0, 13)
6.8 (10.7)
[1]
0 (0, 6)
3.8 (6.4)
[3]
1 (0, 8.5)
5.4 (8.3)
[Missing values] *Interquartile range **Standard deviation
Table 4. Difference between means and odds ratios for psychological measures at 3 and 6 months comparing
participants in the nodule group to those in the normal CT group.
Psychological Measure Difference
between means
(95 %CI) at 3 months
Difference
between means
(95 %CI) at 6
months
P-value for
difference
between
means over
time
Positive and Negative Affect Schedule (PANAS)
Positive affect score* 1.17 (-0.67, 3.01) 1.46 (-0.39, 3.30) P = 0.76
Negative affect score* 0.13 (-1.34, 1.60) -0.05 (-1.52, 1.42) P = 0.79
Lung Cancer Worry Scale
Impact of worry * -0.01 (-0.39, 0.37) -0.15 (-0.53, 0.24) P = 0.36
Health Anxiety Subscale (HAS)** -1.00 (-2.35, 0.35) -0.83 (-2.18, 0.52) P = 0.71
Impact of Events Scale
Intrusion score** -0.73 (-2.37, 0.91) -0.24 (-1.88, 1.40) P = 0.45
Avoidance score** -1.99 (-4.18, 0.21) 0.88 (-1.32, 3.08) P = 0.003
Odds ratios
(95 %CI) at 3 months
Odds ratios
(95 %CI) at 6
months
P-value for
difference
between odds
ratios over
time
Lung Cancer Worry Scale
How worried are you about getting lung cancer
someday?* (worried vs. not worried)
1.07 (0.32, 3.53) 0.63 (0.19,2.13) P = 0.41
What is your current anxiety level about the results
of future tests/treatments?* (anxious vs. not
anxious)
1.09 (0.31, 3.85) 1.42 (0.41, 4.92) P = 0.70
Illness Perception Questionnaire
(IPQ-LC)
What I do can affect my risk of getting lung cancer*
(agree vs. disagree)
0.79 (0.29, 2.16) 1.20 (0.40, 3.61) P = 0.56
When I think about my risk of getting lung cancer I
get upset* (agree vs. disagree)
0.80 (0.18, 3.51) 0.87 (0.20, 3.81) P = 0.90
I do not know how likely it is that I might get lung
cancer* (agree vs. disagree)
1.13 (0.51, 2.51) 0.57 (0.26, 1.26) P = 0.15
Finding lung cancer early can improve my chances of
survival* (agree vs. disagree)
1.39 (0.33, 5.93) 0.85 (0.22, 3.26) P = 0.58
Lung cancer would have a big impact on my life**
(agree vs. disagree)
1.17 (0.15, 8.91) 0.78 (0.10, 6.11) P = 0.72
Lung cancer lasts for a long time* (agree vs. disagree) 1.14 (0.40, 3.22) 0.86 (0.31, 2.42) P = 0.61
A blood screening test can accurately detect lung
cancer* (agree vs. disagree)
1.33 (0.42, 4.17) 1.58 (0.51, 4.92) P = 0.76
Lung Cancer Risk Perception
What are the chances that you will develop lung
cancer over the next 5 years?* (high vs. low)
0.85 (0.25, 2.91) 1.85 (0.54, 6.33) P = 0.21
Compared to other people of your age and sex, how
likely are you to develop lung cancer over the next 5
years?* (more vs. less)
0.75 (0.32, 1.77) 1.63 (0.68, 3.91) P = 0.13
*Adjusted for study centre, age group, gender, smoking status, time and baseline.
**Adjusted for study centre, age group, gender, smoking status and time.
Table 5. Difference between loge transformed means for continuous psychological measures at 3 and 6
months comparing participants in the nodule group to those in the normal CT group.
Psychological Measure Difference
between loge
transformed
means
(95 %CI) at 3
months
Difference
between loge
transformed
means
(95 %CI) at 6
months
P-value for
difference
between loge
transformed
means over time
Negative Affect Schedule (PANAS)* 0.005 (-0.07, 0.08) -0.02 (-0.10, 0.06) p = 0.50
Lung Cancer Worry Scale* -0.004 (-0.10, 0.09) -0.05 (-0.15, 0.04) p = 0.23
Health Anxiety Subscale (HAS)** -0.20 (-0.40, 0.01) -0.17 (-0.38, 0.03) p = 0.76
Impact of Events Scale – Intrusion Score** -0.20 (-0.48, 0.07) -0.09 (-0.36, 0.18) p = 0.34
Impact of Events Scale – Avoidance Score** -0.34 (-0.65, -0.04) -0.06 (-0.36, 0.24) p = 0.04
*Adjusted for study centre, age group, gender, smoking status, time and baseline.
**Adjusted for study centre, age group, gender, smoking status and time.
Supplementary table 1. Psychological measures included in the questionnaires, with a brief description of each measure.
Psychological Measure Administered
at baseline
Administered
at 1, 3 & 6
months
Description References
Positive and negative affect schedule
(PANAS)
Positive affect score
Negative affect score
  Two 10-item scales containing positive
and negative statements, with 5-point
Likert scale (1-5) responses to give a score
for each scale of 10-50*. Cronbach’s alpha
for positive and negative scales ranges
from 0.84-0.90 dependent on the
reporting period used (ranging from “at
the moment” to “in general”).
Watson D, Clark LA, Tellegen A. Development and validation of
brief measures of positive and negative affect: The PANAS
scales. Journal of Personality and Social Psychology.
1988;54(6):1063-70.
Crawford JR, Henry JD. The positive and negative affect
schedule (PANAS): construct validity, measurement properties
and normative data in a large non-clinical sample. The British
journal of clinical psychology / the British Psychological Society.
2004;43(Pt 3):245-65. Epub 2004/08/31.
Lung cancer worry scale (LCWS)
1) How worried are you about getting lung
cancer someday?
2) How much does your worry affect your
mood?
3) How much does your worry affect your
ability to perform your daily activities?
4) What is your current anxiety level about
the results of future tests/treatments?
  Modified from the cancer worry scale by
changing breast cancer to lung cancer and
by changing mammograms to future
tests/treatments. Four questions with 5-
point Likert scale responses. Questions 2
and 3 were combined to give an impact of
worry score (range 2-10)*. Answers to
questions 1 and 4 were dichotomised as
"not worried" vs. "worried" and "not
anxious" vs. "anxious". "Sometimes"
responses were categorised as "worried"
or "anxious." Cronbach’s alpha for the
scale used in relation to breast and
prostate cancer ranges from 0.71 to 0.86.
Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A.
Psychological side effects of breast cancer screening. Health
Psychology. 1991;10(4):259-67.
Brain, K., Norman, P., Gray, J., & Mansel, R. (1999). Anxiety and
adherence to breast selfexamination in women with a family
history of breast cancer. Psychosomatic Medicine, 61, 181-187.
Cohen, L., Fouladi, R. T., Babaian, R. J., Bhadkambar, V. A.,
Parker, R. A., Taylor, C. C., … Basen-Engquist, K. (2003). Cancer
worry is associated with abnormal prostate specific antigen
levels in men participating in a community screening program.
Cancer Epidemiology, Biomarkers & Prevention, 12, 610-617.
McCaul, K. D., Branstetter, A. D., O’Donnell, S. M., Jacobson, K.,
& Quinlan, K. B. (1998). A descriptive study of breast cancer
worry. Journal of Behavioral Medicine, 21, 565- 579.
Bowen, D. J., Christensen, C. L., Powers, D., Graves, D. R., &
Anderson, C. A. (1998). Effects of counseling and ethnic identity
on perceived risk and cancer worry in African American women.
Journal of Clinical Psychology in Medical Settings, 5, 365-379.
Health anxiety subscale (HAS)  One of ten subscales of the health
orientation scale measuring presence of
anxious feelings associated with a
person's physical health. Five questions
with 5-point Likert scale (0-4) responses to
Snell WE, Johnson G, Lloyd PJ, Hoover MW. The Health
Orientation Scale: A measure of psychological tendencies
associated with health. European Journal of Personality.
1991;5(2):169-83.
give a score of 0-20*. Cronbach’s alpha
=0.82.
Impact of events scale (IES)
1) Intrusion score
2) Avoidance score
 Adapted from the original scale used for
bereaved individuals by changing the
referent event to “being tested for lung
cancer”. Fifteen questions covered
intrusive thoughts and avoidant behaviour
following lung cancer screening, with 4-
point Likert scale (0-3) responses to give
an avoidance score ranging from 0-24*
and an intrusion score ranging from 0-21*.
Cronbach’s alpha for the original scale
=0.78 for the intrusion score and 0.82 for
the avoidance score.
Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a
measure of subjective stress. Psychosomatic medicine.
1979;41(3):209-18. Epub 1979/05/01.
Illness perception questionnaire (IPQ-R)
1) What I do can affect my risk of getting
lung cancer
2) When I think about my risk of getting
lung cancer I get upset
3) I do not know how likely it is that I might
get lung cancer
4) Finding lung cancer early can improve my
chances of survival
5) Lung cancer would have a big impact on
my life
6) Lung cancer lasts for a long time
7) A blood screening test can accurately
detect lung cancer
  Based on the revised illness perception
questionnaire, assessing emotional
response generated by illness. Seven
questions, each selected as the item with
the highest factor loading in each subscale
in a study of ovarian cancer screening,
with 5-point Likert scale (1-5) responses.
Answers were dichotomised to "agree" vs.
"disagree". "Neutral" responses were
categorised as "disagree." Cronbach’s
alpha for the subscales ranges from 0.79-
0.89.
Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick
D. The Revised Illness Perception Questionnaire (IPQ-R).
Psychology & Health. 2002;17(1):1-16.
Lancastle D, Brain K, Phelps C. Illness representations and
distress in women undergoing screening for familial ovarian
cancer. Psychology & Health. 2011;26(12):1659-77.
Lung cancer risk perception
1) Absolute risk (What are the chances that
you will develop lung cancer over the next 5
years?)
2) Relative risk (Compared to other people
of your age and sex, how likely are you to
develop lung cancer over the next 5 years?)
  Assessed awareness of risk of developing
lung cancer. Absolute risk responses
ranged from 1 in 1000 to ≥ 1 in 10 (don't 
know option included), dichotomised to
"low risk" (1 in 1000 to 1 in 250 and don't
know) vs. "high risk" (1 in 100 to 1 in 10).
Relative risk was assessed using 6 possible
responses (don't know option included)
ranging from a lot less likely to much more
likely, dichotomised to "less likely" vs.
"more likely." Don't know responses were
categorised as "less likely."
Questions developed for the ECLS study.
*Higher score indicates a greater degree of the psychological outcome.
Highlights
Pulmonary nodules are commonly found on CT scans screening for lung cancer (LC)
Some non-UK studies show negative psychological impacts of pulmonary nodule
diagnosis
We explored psychological impacts of nodule diagnosis during LC screening in the UK
There was little impact on affect, health anxiety, worry, illness perception or risk
perception
There were fewer short-term avoidance symptoms in those diagnosed with nodules
